At the NYU Cancer Institute, members of the Hematologic Malignancies Research Group are researching the etiology and treatment of blood and bone marrow cancers, which includes lymphoma, leukemia, and multiple myeloma. Our investigations include:
Clinical Trials of Targeted Therapies for Lymphoma
- Antibody-drug conjugates that target lymphoma-specific antibodies in diffuse large B-cell and follicular lymphoma.
- Treatment platforms that combine targeted agents with proteasome inhibition in low-grade and mantle-cell lymphoma and targeted therapies that work against cell-cycle regulatory proteins in peripheral T-cell lymphoma.
- Inhibitors of downstream signaling pathways in Hodgkin's lymphoma.
- New treatments for cutaneous T-cell lymphoma (mycosis fungoides), including a better understanding of the role of Th17.
Molecular Biology and Immunomodulatory Therapies
- The molecular basis of malignant transformation, how the microenvironment of a tumor regulates gene expression, and the effects of gene regulation on cancer growth
- The mechanisms controlling stem cell/progenitor differentiation.
- T-cell transformation in leukemia.
- The role of the systemic immune system as a predictor of response to therapy and of relapse.
Clinical Trials in Myeloma
- Novel proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies for treating newly diagnosed and relapsed myeloma
- Approaches to asymptomatic myeloma, including monoclonal antibodies, and herbal products
- New growth factors for supportive care of patients with myeloma
- In bone marrow and stem cell transplantation, combinations of new drugs and traditional chemotherapy for transplant conditioning, combinations of drugs to enhance stem cell collection, and new drugs for maintaining response after bone marrow transplant
- Investigations into the pathogenesis of myeloma including genetics, adhesion molecules in bone marrow and antigens on myeloma cells, and of herbal products in the treatment of myeloma